Effective treatment with intravenous immunoglobulins reduces autoreactive T-cell response in patients with CIDP

Abstract

Our data demonstrate that immunomodulatory treatment with IVIgs on a long-term basis reduces the autoreactive T-cell response against PMP-22 and P2-antigens, which may be influenced by the altered maintenance of CD8 and CD4 effector/memory T-cell subsets towards a more anti-inflammatory immune status. Elevated PMP-22 and P2-specific T-cell responses may serve as predictors for treatment responsiveness to IVIgs warranting validation in larger studies.

Differences in peripheral myelin antigen-specific T cell responses and T memory subsets in atypical versus typical CIDP

“…We confirmed or previous findings that changes of the T memory compartment is a common finding especially in untreated patients [8, 17], which is in contrast to Sanvito and colleagues who showed no differences in T cell subpopulation [23]. In the present study, we detected elevated TEM and TCM primarily in atypical CIDP patients.…”

“…CIDP patients who met the diagnostic criteria of European Federation of Neurological Sciences (EFNS) 2010 were divided into “typical” vs. “atypical” according to EFNS 2010 [20]. Therapy response was defined as an improvement of ≥2 in Medical Research Council (MRC) sum score in 2 different muscle groups, an improvement of ≥1 in Inflammatory Neuropathy Cause and Treatment (INCAT) score (excluding changes in arm function from 0 to 1) or alternatively an improvement of ≥50% of the walking distance as described previously [8]. Patients and controls were recruited in the outpatient clinic of the Department of Neurology, Charité University Medicine Berlin.…”

Stroke induces specific alteration of T memory compartment controlling auto-reactive CNS antigen-specific T cell responses

“…Flow cytometric analysis of human lymphocyte subsets in EDTA whole blood was performed as described recently [27]. Briefly, the following mouse anti-human samples were acquired on a ten-color Navios flow cytometer and analyzed using Navios Software (Beckman Coulter).…”

A prospective study comparing tryptophan immunoadsorption with therapeutic plasma exchange for the treatment of chronic inflammatory demyelinating polyneuropathy*

“…None of these antibodies have been found in a majority of patients, so a heterogeneous pathogenesis underlying CIDP is likely . Based on the fact that there is also increasing evidence of underlying cellular immune mechanism, a leading immunomodulatory effect of PE and IA in CIDP may be discussed. Considering that CIDP is not a uniform disease but consists of heterogeneous variants with different treatment responsiveness, different underlying immune mechanisms might be the cause.…”